Pharmacologic agents for the treatment of acute bipolar mania. (Q34052819)

30 July 2017

1 reference

title

Pharmacologic agents for the treatment of acute bipolar mania. (English)

1 reference

30 July 2017

1 reference

McElroy SL

1 reference

30 July 2017

Keck PE Jr

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 September 2000

1 reference

30 July 2017

published in

Biological Psychiatry

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

30 July 2017

page(s)

539-557

1 reference

Gabapentin in the acute treatment of refractory bipolar disorder.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Response to clozapine in acute mania is more rapid than that of chlorpromazine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Induction of mania by risperidone resistant to mood stabilizers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Olanzapine compared to lithium in mania: a double-blind randomized controlled trial

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

The efficacy of lamotrigine in rapid cycling and non–rapid cycling patients with bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Clozapine for treatment-refractory mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Topiramate as add-on treatment for patients with bipolar mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Effect of gabapentin (Neurontin) [corrected] on mood and well-being in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Quetiapine for treatment-resistant mania.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Clinical Factors in Lithium Carbonate Prophylaxis Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Clinical experience with risperidone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Risperidone treatment for juvenile bipolar disorder: a retrospective chart review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Mood stabilizer combinations: a review of safety and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

A double-blind comparison of valproate and lithium in the treatment of acute mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Acute treatment of bipolar disorder with adjunctive risperidone in outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Lithium-carbonate treatment in depression and mania. A longitudinal double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Clozapine in the treatment of refractory psychotic mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Tiagabine Appears Not to Be Efficacious in the Treatment of Acute Mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Comparative Effects of Lithium and Chlorpromazine in the Treatment of Acute Manic States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Controlled evaluation of lithium and chlorpromazine in the treatment of manic states: An interim report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Pharmacologic loading in the treatment of acute mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Anticonvulsants in the treatment of bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Placebo effect in randomized, controlled studies of acute bipolar mania and depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Importance of Psychiatric Diagnosis in Prediction of Clinical Drug Effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Drug treatment of mania: a critical review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Use of topiramate, a new anti-epileptic as a mood stabilizer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Olanzapine in treatment-resistant bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Open-label adjunctive topiramate in the treatment of bipolar disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Risperidone treatment of bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Update on the mechanism of action of antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Doubleblind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Re: Hypomania associated with risperidone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Effects of carbamazepine and lithium on affective disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Treatment of social phobia with gabapentin: a placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Placebo-controlled study of gabapentin treatment of panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

A Comparison of Lithium Carbonate and Chlorpromazine in Mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Valproate in the treatment of acute mania. A placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Correlates of antimanic response to carbamazepine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

The pharmacologic basis of antiepileptic drug action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Gabapentin in the treatment of bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Manic symptoms associated with initiation of risperidone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

The treatment of manic psychoses by the administration of lithium salts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Risperidone in HIV-related manic psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Carbamazepine compared with lithium in the treatment of mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

A Double-Blind Comparison of Lithium and Chlorpromazine in the Treatment of Manic States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Treatment of acute bipolar depression: a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Letter: How blind is the double-blind?: an assessment in a lithium-prophylaxis study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Treatment of acute mania with gabapentin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Efficacy of lithium as acute treatment of manic-depressive illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Depression during mania. Treatment response to lithium or divalproex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Comparison of efficacy of lithium carbonate and chlorpromazine in mania. Report of collaborative study group on treatment of mania in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

A summary of mechanistic hypotheses of gabapentin pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

7 January 2021

Respiridone and mania

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Treatment of Refractory Rapid Cycling Bipolar Disorder With Risperidone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Adjunctive Use of Olanzapine in Mood Disorders: Five Case Reports

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

Clinical predictors of acute response with olanzapine in psychotic mood disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900961-6

10.1016/S0006-3223(00)00961-6

7 January 2021

Identifiers

DOI

1 reference

30 July 2017

1 reference